Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Edwards Lifesciences (EW) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks ...

Financial Data and Key Metrics Changes - For Q2 2024, Teleflex reported revenues of $749.7 million, a 0.9% increase year-over-year on a GAAP basis. Adjusted revenues, excluding the Italian payback measure, were $763.5 million, up 2.7% year-over-year [7][8] - Adjusted earnings per share for the second quarter was $3.42, reflecting a 0.3% increase year-over-year [20][28] - Adjusted gross margin was 60.8%, a 180 basis point increase compared to the prior year [19][28] Business Line Data and Key Metrics Changes - Vascular access revenues increased 4.8% year-over-year to $181.1 million [10] - Interventional revenues rose 13.8% year-over-year to $141.2 million, driven by strong performance in various product lines [11] - Anesthesia revenues increased 2.3% year-over-year to $102.5 million [12] - Surgical business revenues grew 6.4% year-over-year to $111.3 million, with notable growth in instrumentation and chest drainage [12] - Interventional urology revenues increased 7.1% year-over-year to $83.1 million, driven by Barrigel revenue following the acquisition of Palette Life Sciences [12] Market Data and Key Metrics Changes - Americas revenues were $426.8 million, a 0.6% increase year-over-year [8] - EMEA revenues increased 9.8% year-over-year to $160.9 million, attributed to improved product availability and utilization [9] - Asia revenues were $87 million, a 4% increase year-over-year, impacted by a doctors' strike in South Korea [9] Company Strategy and Development Direction - The company is focusing on expanding its manufacturing capacity for intra-aortic balloon pumps and catheters to meet increased demand [15] - Teleflex is committed to a disciplined capital allocation strategy, including a $500 million share repurchase program while continuing to pursue M&A opportunities [22][23] - The acquisition of Palette Life Sciences is performing above expectations, with revenue guidance for Palette increased to $70 million to $72 million for 2024 [17][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential from intra-aortic balloon pumps, anticipating incremental revenue in Q4 2024 and into 2025 [25][30] - The company expects to see continued growth in Asia and is optimistic about maintaining market share in the intra-aortic balloon pump market [15][34] - Management highlighted the importance of innovation and product launches in driving future growth [30][54] Other Important Information - The company recognized a $15.8 million increase in reserves related to the Italian payback measure, impacting revenue within the EMEA segment [6][7] - Cash flow from operations for the first half of 2024 was $204.5 million, an increase from $170.6 million in the prior year [20] Q&A Session Summary Question: Update on Intra-Aortic Balloon Pumps - Management noted strong quote activity following FDA communications and expects significant market share gains in the coming quarters [33][34] Question: Margin Profile of Intra-Aortic Balloon Pumps - The margin profile for the initial pump sales is slightly dilutive, while subsequent catheter sales are expected to be accretive [37][66] Question: M&A Strategy and Share Buyback - Management clarified that the share repurchase program does not signal a shift away from M&A; both strategies will continue concurrently [36][61] Question: Interventional Urology Business Update - The interventional urology segment is expected to improve in the second half of the year, driven by the performance of Barrigel and the completion of sales rep training [49][56]

Teleflex (TFX) reported $749.69 million in revenue for the quarter ended June 2024, representing a year-overyear increase of 0.9%. EPS of $3.42 for the same period compares to $3.41 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $763.39 million, representing a surprise of -1.79%. The company delivered an EPS surprise of +2.70%, with the consensus EPS estimate being $3.33. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Teleflex (TFX) came out with quarterly earnings of $3.42 per share, beating the Zacks Consensus Estimate of $3.33 per share. This compares to earnings of $3.41 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 2.70%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.07 per share when it actually produced earnings of $3.21, delivering a surprise of 4.56%. Over the last four quarters, the c ...

WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 16, 2024, to shareholders of record at the close of business on August 15, 2024. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to ...

WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 16, 2024, to shareholders of record at the close of business on August 15, 2024. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to ...

WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the second quarter ended June 30, 2024. Second quarter financial summary GAAP revenue of $749.7 million, up 0.9% compared to the prior year period Adjusted revenue of $763.5 million, excluding the impact from increases in our reserves related to the Italian payback measure pertaining to prior years, up 2.7% compared to the prior year period, up 3.4% on a constant currency bas ...

Core Viewpoint - Analysts project that Teleflex will report quarterly earnings of $3.33 per share, reflecting a decline of 2.4% year over year, with revenues expected to reach $763.39 million, an increase of 2.7% from the same quarter last year [10] Revenue Estimates - 'Net Revenues- Anesthesia' is estimated to be $104.01 million, indicating a change of +3.2% from the year-ago quarter [2] - 'Geographic Revenues- EMEA' is expected to be $157.16 million, showing a change of +6.3% from the year-ago quarter [3] - 'Net Revenues- Interventional Urology' is projected at $83.48 million, reflecting a change of +7.3% from the prior-year quarter [5] - 'Net Revenues- Surgical' is forecasted to reach $111.50 million, indicating a change of +5.2% from the prior-year quarter [6] - 'Revenues- OEM (Original Equipment Manufacturer and Development Services)' is estimated at $88.27 million, suggesting a change of +5% year over year [8] - 'Geographic Revenues- Americas' is likely to reach $432.19 million, indicating a change of +1.8% year over year [9] - 'Net Revenues- Interventional' is estimated at $137.89 million, reflecting a change of +10.5% year over year [11] - 'Net Revenues- Other' is projected to be $55.13 million, indicating a change of -27.5% year over year [12] - 'Net Revenues- Vascular Access' is expected to reach $181.31 million, showing a year-over-year change of +4.3% [14] - 'Geographic Revenues- Asia' is forecasted to be $87.90 million, indicating a change of +1.4% from the year-ago quarter [15] Earnings Estimate Revisions - Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter, indicating that analysts have not changed their initial forecasts during this period [4] Stock Performance - Teleflex shares have experienced a change of +5.4% in the past month, compared to a -0.4% move of the Zacks S&P 500 composite, with a Zacks Rank 3 (Hold) suggesting that TFX is expected to mirror overall market performance in the near future [7]

The Ringer™ PBC is a rapid-exchange 0.014" compatible catheter with a unique helical balloon at its working end. When inflated, this balloon approximates a hollow cylinder with a large central perfusion lumen. These characteristics allow for continuous coronary blood flow during prolonged inflations.2 The Ringer™ PBC is indicated for balloon dilatation of coronary artery or coronary bypass graft stenoses where the physician desires distal blood perfusion during balloon inflation for the purpose of improving ...